Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioTime and its subsidiary Embryome Sciences, have signed a manufacturing and distribution agreement with International Stem Cell, through its wholly-owned subsidiary Lifeline Cell Technology, to jointly produce and distribute hundreds of new standardized human and animal stem cell lines, along with corresponding data and reagents.
Subscribe to our email newsletter
The mutual goal is to provide the ‘picks and shovels’ for scientists mining the stem cell field for therapeutics in the emerging field of regenerative medicine and pharmaceutical drug discovery.
These stem cell lines called ‘progenitor’ cell lines possess the potential to expand and become specific types of tissues and cells such as heart, skeletal muscle, bone, retinal, nerve, pancreas and others.
Under the collaborative production and manufacturing agreement, the parties intend to manufacture ESpy cell lines, as well as a host of supplies scientists will utilize in the field of stem cell research.
The progenitor cell lines will be produced and distributed in joint efforts utilizing Embryome Sciences’s ‘Embryomics’ technology, International Stem Cell’s proprietary parthenogenetic stem cell lines derived from unfertilized human eggs and technology and approved hES cell lines licensed from the Wisconsin Alumni Research Foundation.
Embryome Sciences also plans to develop and market other products for use by stem cell researchers, including growth and differentiation factors that can permit researches to manufacture specific cell types from embryonic stem cells, and purification tools useful to researchers in quality control of products for regenerative medicine.